Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoscopic healing in small intestinal Crohn’s disease treated with guselkumab
ChiCTR2500110828Phase 4Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of guselkumab in Crohn's disease, sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Endoscopic remission rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2500110828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110828.